Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kattie Khadar"'
Autor:
Janelle Robinson, Terry Hyslop, William Kevin Kelly, Naomi B. Haas, Brooke Kennedy, Swati Nanda, Monica McGuire, Andrea B. Apolo, Stephen M. Keefe, David J. Vaughn, Jianqing Lin, Kattie Khadar, Jean H. Hoffman-Censits
Publikováno v:
Journal of Clinical Oncology. 32:e15519-e15519
e15519 Background: There is no standard second line therapy for metastatic urothelial cancer (mUC) following platinum chemotherapy (CT). Taxanes have shown clinical activity in this setting. Cabazi...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::941f02a2526f09730cc9866db56ae234
https://doi.org/10.1200/jco.2014.32.15_suppl.e15519
https://doi.org/10.1200/jco.2014.32.15_suppl.e15519
Autor:
Maria Liza Lindenberg, Peter L. Choyke, David J. Liewehr, Andrea B. Apolo, Yolanda McKinney, Kattie Khadar, Benjamin A. Weinberg, Karen A. Kurdziel, Seth M. Steinberg
Publikováno v:
Journal of Clinical Oncology. 32:329-329
329 Background: 18F-NaF has shown improved sensitivity for bone imaging when compared to conventional planar imaging or SPECT/CT using 99mTc-MDP. We compared the number of bone lesions detected on 18F-NaF versus 18F-FDG in urothelial cancer pts with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::838771099033a893127f426d3adcb03b
https://doi.org/10.1200/jco.2014.32.4_suppl.329
https://doi.org/10.1200/jco.2014.32.4_suppl.329
Autor:
Piyush K. Agarwal, Les R. Folio, Howard L. Parnes, William D. Figg, Maria J. Merino, John Wright, James L. Gulley, Andrea B. Apolo, Peter L. Choyke, Ravi A. Madan, Donald P. Bottaro, Jane B. Trepel, Seth M. Steinberg, Philip M. Arlen, Jeffrey Schlom, Maria Liza Lindenberg, William L. Dahut, Kattie Khadar, Karen A. Kurdziel
Publikováno v:
Journal of Clinical Oncology. 31:TPS4589-TPS4589
TPS4589 Background: Accumulating evidence supports MET as a therapeutic target in urothelial carcinoma. Activated MET can promote angiogenesis and tumor growth by upregulating VEGF and may play a role in urothelial carcinoma pathogenesis. Cabozantini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::260e6578c72de5c476bcc9309c112331
https://doi.org/10.1200/jco.2013.31.15_suppl.tps4589
https://doi.org/10.1200/jco.2013.31.15_suppl.tps4589
Autor:
Kattie Khadar, Amelia Summerell, Young H. Lee, Kathryn Compton, William D. Figg, Donald P. Bottaro, James L. Gulley, Piyush K. Agarwal, Andrea B. Apolo, Howard L. Parnes, Fabiola Cecchi, William L. Dahut
Publikováno v:
Journal of Clinical Oncology. 31:314-314
4543 Background: Mounting evidence supports Met as a therapeutic target in urothelial cancer (UC). Activated Met can promote angiogenesis and tumor growth by upregulating VEGF and may play a role in UC pathogenesis. Cabozantinib inhibits VEGFR2 and M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66eb88d8dbb488f5ae63b7227dcbd664
https://doi.org/10.1200/jco.2013.31.6_suppl.314
https://doi.org/10.1200/jco.2013.31.6_suppl.314